Jefferies Says Cost-Effectiveness Analysis Suggests Broad Seattle Genetics (SGEN) Adcetris First-Line Use
Tweet Send to a Friend
Jefferies analyst Thomas Wei reiterated a Buy rating and $53 price target on Seattle Genetics (NASDAQ: SGEN) saying a cost-effectiveness ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
